Merck reported a strong first quarter post-merger with a 7% sales increase and EPS growth from $0.74 to $0.83 on a non-GAAP basis. Management expressed confidence in integration efforts and highlighted robust performance from key products, supporting a positive outlook despite some external challenges.

[1]